Impact of repurposed drugs on the symptomatic COVID-19 patients
Fecha
2020Autor
Hussain, Iqbal
Hussain, Afzal
Alajmi, Mohamed F.
Rehman, Md. Tabish
Amir, Samira
Resumen
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel
coronavirus capable of causing coronavirus disease 2019 (COVID-19), was declared as a
global public health emergency on January 30, 2020, by the World Health Organization.
In this devastating situation, precautionary measures, early diagnosis, and repurposed
drugs appear to be timely and decisive factors by which to handle this problem until the
discovery of an effective, dedicated vaccine or medicine is made. Currently, some
researchers and clinicians have claimed evidence exists in favor of the use of some
antimalarial drugs (chloroquine, hydroxychloroquine) antiviral drugs (remdesivir,
favipiravir, lopinavir, ritonavir, umifenovir) vitamins, traditional Chinese medicines, and
herbal medicines against SARS-CoV-2 infection. Based on the available literature, this
review article sought to highlight the current understanding of the origin, transmission,
diagnosis, precautionary measures, infection and drug action mechanisms, therapeutic role,
and toxicities of targeted drugs for the prevention and cure of COVID‐19. This review may
be useful for developing further strategies as a blueprint and understanding the mentioned
drugs’ mechanismsto elucidate the possible target of action by which to successfully freeze
the replication of the SARS-CoV-2 virus.
Palabras clave
SARS-CoV-2; COVID-19; Diagnosis; Precautionary measures; Chloroquine; Hydroxychloroquine; Remdesivir; Favipiravir; Lopinavir; Ritonavir; Umifenovir; Drug toxicitiesEnlace al recurso
https://doi.org/10.1016/j.jiph.2020.11.009Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.